Veracyte, Inc.
VCYT
Rang in aandelen
#4382
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aandeelprijs
$44.53
Marktkapitalisatie
$3.58B
Verandering (1 dag)
1.66%
Verandering (1 jaar)
21.49%
Land
US
Handel Veracyte, Inc. (VCYT)
Categorie
Healthcare
EPS voor Veracyte, Inc. (VCYT)
EPS per June 2026 TTM: $1.44
Volgens de laatste financiële rapporten en de aandelenkoers van Veracyte, Inc. is de huidige EPS van het bedrijf (TTM) $1.44. Eind 2023 had het bedrijf een EPS van $-1.02, een stijging ten opzichte van de EPS van 2022 die $-0.51 bedroeg.
EPS-geschiedenis van Veracyte, Inc. van 2011 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.44 | 350.00% |
| 2024 | $0.32 | -131.37% |
| 2023 | $-1.02 | 100.00% |
| 2022 | $-0.51 | -54.05% |
| 2021 | $-1.11 | 68.18% |
| 2020 | $-0.66 | 144.44% |
| 2019 | $-0.27 | -56.45% |
| 2018 | $-0.62 | -31.87% |
| 2017 | $-0.91 | -16.51% |
| 2016 | $-1.09 | -16.15% |
| 2015 | $-1.30 | -4.41% |
| 2014 | $-1.36 | -77.89% |
| 2013 | $-6.15 | 369.47% |
| 2012 | $-1.31 | 28.43% |
| 2011 | $-1.02 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $18.62 | 1,193.06% |
US
|
|
| $5.65 | 292.36% |
US
|
|
| $-1.36 | -194.44% |
US
|
|
| - | - |
CN
|
|
| $5.09 | 253.47% |
US
|
